Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Revenues Drop 24 Percent, Losses Narrow in Q4

The revenue numbers in this article have been corrected from those reported earlier today.

 

NEW YORK, Feb. 10 (GenomeWeb News) - Sequenom today reported total reported that fourth-quarter revenues fell 24 percent to $6.1 million from $8 million for the year-ago quarter.

 

The company spent $3.9 million on R&D for the quarter, down from $6.4 million in the year-ago period.

 

The company cut its net loss to $6.9 million from $10.1 million for the fourth quarter of 2003, a 32-percent improvement for the San Diego-based company.

 

Sequenom reported cash and cash equivalents of $38 million as of Dec. 31, 2004.

 

Looking ahead, Sequenom said in 2005 it plans to launch a product with "enhanced multiplexing levels and advanced gene expression software," and release its first analyte specific reagents for public-domain genetic tests such as Factor V and cystic fibrosis.

 

Sequenom yesterday announced the resignation of CEO Toni Schuh.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.